Sara ReardonSocial Links NavigationSara Reardon is a freelance journalist based in Bozeman, Mont. She is a former staff reporter at Nature, New Scientist and Science and has a master's degree in molecular biology. Latest articles by Sara Reardon Popular weight-loss drug Wegovy now approved for heart disease. Here's what we know. By Sara Reardon published 24 March 24 The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works. Medicine & Drugs Sign up for the Live Science daily newsletter nowGet the world’s most fascinating discoveries delivered straight to your inbox.Contact me with news and offers from other Future brandsReceive email from us on behalf of our trusted partners or sponsors LATEST ARTICLES1The universe's 'missing matter' may have finally been found2Experimental 'Ozempic pill' shows promise in treating type 2 diabetes3NASA rover reveals signs of crucial life-sustaining process on Mars4'Useless' female organ may actually support the ovaries, study finds5A mysterious, 100-year solar cycle may have just restarted
Popular weight-loss drug Wegovy now approved for heart disease. Here's what we know. By Sara Reardon published 24 March 24 The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works.
